{"id":2305,"date":"2014-12-01T12:02:00","date_gmt":"2014-12-01T11:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/initialtherapie-des-idiopathischen-parkinson-syndroms"},"modified":"2022-03-17T14:13:06","modified_gmt":"2022-03-17T13:13:06","slug":"initialtherapie-des-idiopathischen-parkinson-syndroms","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/initialtherapie-des-idiopathischen-parkinson-syndroms","title":{"rendered":"Initialtherapie des idiopathischen Parkinson-Syndroms"},"content":{"rendered":"<p>Drei Medikamentengruppen werden zur initialen Therapie des idiopathischen Parkinson-Syndroms (IPS) empfohlen: Levodopa (L-Dopa), Dopamin-Agonisten (DoA) und MAO-B-Hemmer (MBH; 1). Levodopa ist der Goldstandard. Leider l\u00e4sst die Wirkung von Levodopa mit der Zeit nach, und es kommt zu motorischen Sp\u00e4tkomplikationen. Daher wurden &#8222;Levodopa-sparende&#8220; Alternativen gesucht und propagiert, insbesondere f\u00fcr j\u00fcngere Patienten. Man glaubt, durch den prim\u00e4ren [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Drei Medikamentengruppen werden zur initialen Therapie des idiopathischen Parkinson-Syndroms (IPS) empfohlen: Levodopa (L-Dopa), Dopamin-Agonisten (DoA) und MAO-B-Hemmer (MBH; 1). Levodopa ist der Goldstandard. Leider l\u00e4sst die Wirkung von Levodopa mit der Zeit nach, und es kommt zu motorischen Sp\u00e4tkomplikationen. Daher wurden &#8222;Levodopa-sparende&#8220; Alternativen gesucht und propagiert, insbesondere f\u00fcr j\u00fcngere Patienten. Man glaubt, durch den prim\u00e4ren [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1436,629,665,1438,1439,4591,1754,3186,376,1939],"class_list":["post-2305","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-anti-parkinson-mittel","tag-l-dopa","tag-levodopa","tag-m-parkinson","tag-parkinson-syndrom","tag-pd-med-studie","tag-pramipexol","tag-rasagilin","tag-ropinirol","tag-selegilin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2305"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2305\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}